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Although there has been a rapid rise in the publication of meta-analyses of genetic association studies, little is
known about their methodological quality. The authors reviewed the quality of 120 randomly selected genetic meta-
analyses published between 2005 and 2007. Data extracted included issues of general relevance and other issues
speciﬁc to genetic epidemiology. Quality was markedly poorer in the 26% of the meta-analyses that accompanied
a report on a primary study. Such meta-analyses were predominantly published in specialist journals, and their
quality was positively associated with the impact factor of the journal. Among the meta-analyses that did not
accompany a primary study, Human Genome Epidemiology reviews tended to score better than the others,
although the comparison was limited by relatively small numbers. Comparison of the overall quality with that of
genetic meta-analyses published before 2000 showed improvement in both conduct and reporting. However, the
quality of the handling of speciﬁc genetic issues remains disappointingly low. For a few key general quality issues,
the authors compared their ﬁndings with ﬁndings in other ﬁelds of medicine and found that general quality was
similar. On the basis of this review, the authors provide practical recommendations for the conduct and reporting of
genetic meta-analyses.
epidemiologic methods; genetics; meta-analysis; principal component analysis
Abbreviations: HuGE, Human Genome Epidemiology; HWE, Hardy-Weinberg equilibrium; PCA, principal component analysis.
Meta-analysis—the pooling of results or data across
a number of studies—is advocated as a valuable tool in
clinical research, not only because it increases the power
to detect an association but also because it helps make sense
of conflicting results. It is particularly useful in genetic ep-
idemiology, where there has been a massive increase in the
number of published primary studies and the proportion of
gene-disease associations that have been replicated is dis-
appointingly low (1).
Genuine population diversity may explain part of the lack
of replication, but the key reasons are probably methodo-
logical, due to small sample sizes and bias (2). Important
biases are publication bias and reporting bias, whereby au-
thors only publish a paper if they obtain statistically signif-
icant findings or only report those associations which reach
statistical significance. One consequence of this is the ‘‘first-
study effect,’’ whereby the first study published on a gene-
disease association suggests a genetic effect that is not
found, or is found with much smaller magnitude, in sub-
sequent studies (3). As a result, new findings are generally
treated skeptically until they have been replicated. Meta-
analysis plays an important role in assessing that replication
and in providing an estimate of the size of the genetic effect.
The importance of evidence synthesis in genetic associa-
tion research is illustrated by Figure 1, which shows the
rapid increase in published meta-analyses of genetic asso-
ciation studies over the last decade. It is less certain whether
this increase has been accompanied by an improvement in
quality. Previous work evaluating the quality of genetic
meta-analyses published up to 2000 showed common flaws
in their conduct and reporting (4–6), which may have led to
bias and misleading results.
In this paper, we review the methods used in recent meta-
analyses of genetic association studies, assess quality, and
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compare that quality with the quality of earlier genetic and
nongenetic meta-analyses. Based on the findings of the re-
view, we provide practical recommendations for the conduct
and reporting of genetic meta-analyses.
MATERIALS AND METHODS
Review of meta-analyses
Identiﬁcation of papers. We identified papers published
in 2005, 2006, and 2007 by searching the HuGE Reviews
Archive (http://www.cdc.gov/genomics/hugenet/reviews_
arch.htm), a database of published meta-analyses of genetic
association studies maintained by the Human Genome Ep-
idemiology Network. For each year, we randomly selected
40 papers that were published in English and that reported
meta-analyses of summary data on gene-disease associa-
tions with binary outcomes. We excluded systematic re-
views that did not contain a quantitative synthesis of
results and meta-analyses based on individual patient data.
Data extraction. Data were extracted using an extraction
form (see Web Figure 1, which is posted on the Journal’s
Web site (http://aje.oxfordjournals.org/)) with explicit defi-
nitions for each field. The topics covered by the form are
listed in Table 1 and include issues of general relevance to
all meta-analyses and other issues that are only of concern in
genetic epidemiology.
For the papers from 2005, data extraction was performed
independently by 2 reviewers. Regular meetings were held
to reach consensus, discuss the reasons for disagreements,
and refine the definitions of the data extraction fields.
The final definitions are given in Web Figure 2 (http://aje.
oxfordjournals.org/). This iterative process reduced appar-
ent disagreements until we found that remaining discrep-
ancies were due to information being missed by one of the
reviewers. For the papers from 2006 and 2007, each article
was reviewed by 1 author, and we addressed the problem of
overlooked information by using a computer program that
searched for a list of keywords in an electronic version of
the article (available on request from the authors).
Indicators of quality. Although our study was designed to
evaluate individual quality components, we also used scores
as convenient summaries of the main features of the papers.
Some aspects of the meta-analysis of genetic association
studies are controversial, but there are some very basic in-
dicators of good practice and good reporting that should
always be present. We created 2 quality scores based on
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Figure 1. Numbers of meta-analyses of genetic association studies published over time, 1966–2007. Articles were obtained through an electronic
MEDLINE search, with no limits on publication year or language. No genetic meta-analyses were published before 1993.
Table 1. Main Topics Covered by the Data Extraction Form Used in
a Review of 120 Meta-Analyses of Genetic Association Studies
Published Between 2005 and 2007
Topics General to
All Meta-Analyses
Topics Speciﬁc to
Genetic Associations
Search strategy Genetic model
Inclusion/exclusion criteria Consideration of
polymorphism prevalence
No. and size of the
meta-analyses
Handling of Hardy-Weinberg
equilibrium
Main outcome measure Use of biomarkers
Use of graphical displays Use of family studies
Assessment of
heterogeneity
Fixed- or random-effects
models
Subgroup analyses
Reporting of study
characteristics
Consideration of
publication bias
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such indicators: a ‘‘general quality score’’ that depends on
aspects relevant to any meta-analysis and a ‘‘genetic quality
score’’ derived from aspects specific to genetics. Twenty-
eight quality indicators were identified—19 for general
quality and 9 for genetic quality—covering both ‘‘positive’’
and ‘‘negative’’ aspects of the conduct and reporting of
genetic meta-analyses. We calculated the 2 quality scores
by summing positive factors and subtracting negative fac-
tors and scaling the results to lie between 0 and 100, using
the theoretical maximum and minimum of the sum.
We then performed a principal component analysis (PCA)
(7), with the aim of assessing whether 1) indicators would
tend to aggregate within the same papers, forming 2 separate
clusters for good and poor quality, and 2) indicators sub-
jectively classified as positive and negative would consis-
tently appear in the right cluster of the PCA analysis.
The analysis was performed for both general and genetic
indicators. We generated new scores by PCA and compared
them with the subjective scores, both formally (correlation
coefficient) and graphically by plotting one against
the other.
The PCA results strongly supported the definition of
positive and negative factors of the general score; the cor-
relation between the subjective and PCA-derived scores was
very high (Pearson correlation coefficient ¼ 0.98; P <
0.0001). Of the 9 quality indicators for the genetic score,
the PCA results supported all but 1 factor, ‘‘consideration of
biomarkers,’’ which was subjectively classified as positive
but was clustered with the other 2 negative factors in the
PCA. After removal of this factor, the correlation between
subjective and PCA-derived scores increased from 0.86 (P<
0.0001) to 0.96 (P < 0.0001). The indicator was therefore
removed from the genetic score. The final items included in
both general and genetic scores are listed in Table 2. The
results of the PCA, including the scatterplots of subjective
versus PCA-derived scores and the component plots, are
shown in Web Figure 3 (http://aje.oxfordjournals.org/).
The component plots show how each individual quality
indicator contributed to the discrimination between good
and poor quality. For the general score (Web Figure 3, part
a), 3 positive factors (duplicate eligibility checking and/or
extraction; forest plot of study-specific results; statistical
methods section in paper) and 2 negative factors (search
strategy not described; inclusion/exclusion criteria un-
clear) seemed to capture most of the variability in quality.
Corresponding items for the genetic score (Web Figure 3,
Table 2. General and Genetic Quality Indicators Used in Quality Scores in a Review of 120 Meta-Analyses of
Genetic Association Studies Published Between 2005 and 2007
Positive Factors
% of
Papers
Negative Factors
% of
Papers
General Quality Indicators
Completely reproducible search strategy 16 Search methods not described 14
Duplicate eligibility checking and/or data extraction 31 Inclusion/exclusion criteria not reported 26
Forest plot of study-speciﬁc results 78 Designs of primary studies unclear 20
Statistical methods section in the paper 92 No details on study characteristics 10
Formal tests for any interactions 10 No details on study-speciﬁc results 18
Measure of size of heterogeneity (e.g., I 2) 31 P values without effect size estimate 2
Reason given for choice of ﬁxed/random effects 51 No assessment of heterogeneity 7
Authors contacted for extra data 25 Unclear whether ﬁxed- or random-effects
models were used
3
Study inﬂuence assessment 20 No assessment of publication bias 29
Quality assessment of individual studies 10
Genetic Quality Indicators
Reason given for choice of genetic model 14 No data on allele/genotype prevalence 59
Consideration of impact of genotyping error 10 Unclear what genetic model was assumed 5
Consideration of impact of population stratiﬁcation 14 No assessment of Hardy-Weinberg
equilibrium
59
Information on linkage disequilibrium 25
Information on haplotypes 10
Quality Scorea, Mean (Standard Deviation)
General score 59.8 (15.8)
Genetic score 30.9 (17.2)
Overall score 51.2 (13.9)
a Quality scores were based on positive and negative indicators of good practice and good reporting. The general
quality score depended on aspects relevant to any meta-analysis, and the genetic quality score was derived from
aspects speciﬁc to genetics. The 2 quality scores were calculated by summing positive factors and subtracting
negative factors and scaling the results to lie between 0 and 100, using the theoretical maximum and minimum of
the sum.
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part c) were 2 positive factors (consideration of impact of
genotyping errors; information on linkage disequilibrium)
and 2 negative factors (no data on allele/genotype preva-
lence; no assessment of Hardy-Weinberg equilibrium
(HWE)).
Subgroup analyses. We investigated whether the quality
of the meta-analyses might be influenced by characteristics
of the published articles, by grouping the papers on the basis
of whether the meta-analysis: 1) accompanied a primary
study; 2) was a Human Genome Epidemiology (HuGE)
review; 3) appeared in a general medicine, genetics, or
specialty journal; or 4) appeared in a journal with a high
impact factor.
Comparisons with previous work
We searched the literature to identify previous reports
of the quality of published meta-analyses in order to look
for evidence of methodological improvement over time
and for differences between genetic and nongenetic
meta-analyses.
We considered all papers included in MEDLINE (US
National Library of Medicine) that had been published be-
tween 1966 and August 2008, using the following search
strategy: (meta-analys* or systematic review*) and (quality
or evaluat* or assessment or survey or appraisal or method-
olog*), with the search field limited to the title of the article.
Reference lists of all relevant papers were scanned for
further potential studies. We limited inclusion to reviews
published in English that had assessed more than 10 meta-
analyses. Since different criteria have been used to evaluate
the quality of meta-analyses, producing problems of com-
parability, we included only those reviews which provided
information on at least 2 of the following 5 items: 1) report-
ing of the search strategy; 2) reporting of the inclusion cri-
teria; 3) reporting of the pooling methods; 4) evaluation of
statistical heterogeneity; and 5) evaluation of publication
bias.
RESULTS
Review of meta-analyses
Selection of studies. The meta-analysis articles were
classified in the HuGE Reviews Archive by area of medi-
cine, as papers on: neoplasms (n ¼ 28); endocrine, nutri-
tional, and metabolic diseases and immunity disorders (n ¼
25); diseases of the circulatory system (n ¼ 18); diseases
of the nervous system and sense organs (n ¼ 16); mental
disorders (n ¼ 12); and other topics (n ¼ 21). Of the 120
papers identified, 74% reported results of 1 or more meta-
analyses, while in the other 26%, investigators reported
results from their own primary study, accompanied by
a meta-analysis based on one of their main findings. The
median number of primary studies included in a paper was
13 (interquartile range, 8–22), while the median number
of separate meta-analyses performed was 2 (interquartile
range, 1–3; range, 1–26). Each of these meta-analyses
included 2–119 primary studies. The median size of the
largest meta-analysis in each of the 120 articles was 11
studies (interquartile range, 8–18). Among the 96 papers
that clearly reported the design of the studies included, 5
meta-analyzed family-based studies, another 4 combined
family studies with population studies, and the rest ana-
lyzed only population-based studies, including case-
control, cohort, and cross-sectional studies or a mixture
of the 3.
Indicators of quality in conduct or reporting. Results for
the individual quality indicators are shown in Table 2. De-
tailed results on all of the other items considered, for the
whole sample and by subgroup, are shown in Web Tables 1–6
(http://aje.oxfordjournals.org/). Overall, the papers scored
better on general indicators than on genetic indicators, al-
though basic issues such as reporting of inclusion/exclusion
criteria and assessment of publication bias were ignored by
more than one-fourth of the meta-analyses. In approximately
one-third of the papers, investigators had performed dupli-
cate checking of eligibility/data extraction and estimated the
magnitude of the between-study heterogeneity along with the
test, suggesting thoroughness in the conduct of the meta-
analysis. Study quality assessment was performed in only
12 meta-analyses. These analyses used different sets of cri-
teria, usually based on checklists developed for the evalua-
tion of epidemiologic studies, with the addition of items
specific to genetics. In only 9 meta-analyses did investigators
evaluate the first-study effect.
Primary study effect. Whether the meta-analysis was the
primary focus of the article or was an accompaniment to the
authors’ own primary study had a large impact on quality.
We accessed supplementary materials posted on a journal’s
or author’s Web site whenever such materials were men-
tioned. Table 3 shows the factors that varied significantly
(P < 0.05) between meta-analyses published with and with-
out an accompanying primary study. The factors all pointed
to poorer quality when the meta-analysis was not the pri-
mary focus, with strong differences for most aspects of the
conduct and reporting of the meta-analysis. The quality was
much lower for both the general quality indicators and the
genetic quality indicators, with differences of 36% (P <
0.0001) and 35% (P < 0.001), respectively. In more than
half of the meta-analyses that accompanied a primary study,
the investigators did not even specify what databases they
had searched.
Quality of HuGE reviews. None of the HuGE reviews
accompanied a primary study, so they were compared with
the other articles that did not include a primary study. There
were 16 (18%) HuGE reviews, 14 published in the American
Journal of Epidemiology and 2 in Genetics in Medicine, and
73 comparator articles.
There was no significant difference in general quality
scores between HuGE reviews and other meta-analyses.
For the genetic score, there was a nonsignificant trend
towards better quality in HuGE reviews (16% difference;
P ¼ 0.090). This reflected a higher proportion of meta-
analyses in which investigators tested for departures from
HWE (63% vs. 47%; P ¼ 0.281) and a higher proportion
of papers in which investigators considered the possibility
of genotyping errors in the primary studies (25% vs. 8%;
P ¼ 0.076). Half of the HuGE reviews, as compared with
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one-fifth of the others (P ¼ 0.021), used pairwise compar-
isons that do not require the assumption of a genetic model.
The tendency toward better reporting of primary study
characteristics in HuGE meta-analyses can be seen in sev-
eral features (Web Tables 3 and 4), particularly for disease
definition (81% vs. 51%; P ¼ 0.029) and for evaluation
of the prevalence of the genetic variant in the population
(81% vs. 44%; P ¼ 0.011).
Impact factor and journal type. The 31 meta-analyses that
accompanied primary studies were generally of poor quality
and were predominantly published in the specialist journals
(81%). Among meta-analyses in papers without a primary
study, no differences in either general or genetic quality
were found between the 3 types of journals. Detailed results
are shown in Web Tables 5 and 6.
We performed a regression analysis to assess whether
the quality scores varied with the (log) impact factor of
the journal. The overall quality score among the 31 meta-
analyses that accompanied primary studies was positively
associated with the impact factor of the journals (P ¼ 0.01),
with such an association being mainly confined to the gen-
eral quality indicators. Among the other 89 articles, neither
the general quality nor the genetic quality showed any trend
with impact factor.
Table 3. Quality Indicators That Varied Signiﬁcantly (P < 0.05) Between Papers With a Meta-
Analysis Only and Papers With a Meta-Analysis Accompanying a Primary Study in a Review of
120 Meta-Analyses of Genetic Association Studies Published Between 2005 and 2007
Quality Indicator
Papers With M-A
Only (n 5 89)
Papers With
M-A 1 Primary
Study (n 5 31) P Value
a
% Mean (SD) % Mean (SD)
General indicators of quality
Search strategy
Databases listed 100 45 <0.001
End date stated 93 35 <0.001
Search terms listed 93 42 <0.001
Inclusion/exclusion criteria reported 92 29 <0.001
Duplicate eligibility assessment 17 0 0.011
Duplicate data extraction 36 3 <0.001
Use of random-effects models 87 48 <0.001
Heterogeneity test 99 77 <0.001
Measure of size of heterogeneity 36 16 0.044
Primary study sizes reported 81 52 0.004
Primary study disease deﬁnitions reported 56 6 <0.001
Primary study ethnicity/location reported 88 42 <0.001
Graphical evaluation of publication bias 55 23 0.002
Statistical test of publication bias 70 26 <0.001
Cumulative meta-analysis 20 3 0.024
Study inﬂuence assessment 25 6 0.036
Genetic indicators of quality
Testing for Hardy-Weinberg equilibrium 49 16 0.001
Allele/genotype counts reported 64 42 0.036
Data on prevalence of polymorphism(s) 51 13 <0.001
Quality scoreb
General score 66.1 (10.6) 41.8 (14.5) <0.0001
Genetic score 34.0 (18.0) 22.2 (11.0) <0.001
Overall score 56.6 (10.2) 36.0 (12.0) <0.0001
Abbreviations: M-A, meta-analysis; SD, standard deviation.
a P values were based on a 2-tailed Fisher’s exact test for quality indicators and the Mann-
Whitney U test for quality scores.
b Quality scores were based on positive and negative indicators of good practice and good
reporting. The general quality score depended on aspects relevant to any meta-analysis, and the
genetic quality score was derived from aspects speciﬁc to genetics. The 2 quality scores were
calculated by summing positive factors and subtracting negative factors and scaling the results to
lie between 0 and 100, using the theoretical maximum and minimum of the sum.
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Comparison with previous work
Previous reviews. The electronic search yielded 957
‘‘hits,’’ from which 73 full-text articles were obtained and
evaluated for eligibility. Four papers were added after cross-
checking of reference lists, and 1 paper was added because it
was known to the authors. Fifty papers were subsequently
excluded, most because of the low number of meta-analyses
considered (10) or the reporting of only 1 of the 5 criteria.
A flow chart detailing inclusion and reasons for exclusion is
presented in Web Figure 4 (http://aje.oxfordjournals.org/).
Table 4 presents the results of the remaining 29 articles,
reporting on 28 reviews. The reviews considered 16–272
meta-analyses. Only 1 review considered the meta-analysis
of genetic association studies, while most of the others fo-
cused on randomized clinical trials. The Oxman and Guyatt
scale, also known as the Overview Quality Assessment
Questionnaire (8), was the most commonly used quality
scale (62%), although it was often accompanied by infor-
mation on additional quality indicators.
Trend in quality over time. By comparing our findings on
recently published meta-analyses with those of Attia et al.
(4) on 37 meta-analyses published before 2000, we can see
improvement over time in both reporting and conduct. Re-
porting of the search methods increased from 65% in older
meta-analyses to 86% in recent meta-analyses (P ¼ 0.008),
and the same was found for reporting of inclusion criteria,
which increased from 49% to 74% (P ¼ 0.005). Improve-
ment in the conduct of meta-analyses is suggested by a sub-
stantial increase in the assessment of heterogeneity (from
76% to 93%; P ¼ 0.005) and an extraordinary increase in
the evaluation of publication bias (from 19% to 71%; P <
0.001). None of the meta-analyses published before 2000
used a formal statistical test to evaluate the presence of
publication bias, as compared with 58% of recent meta-
analyses, the majority of which used Egger’s test (intro-
duced in 1997).
Improvement in genetic quality factors is less marked.
HWE was tested in individual studies in only 24% of the
meta-analyses published before 2000 versus 41% of those
included in our review (P¼ 0.081). No difference was found
for the choice of the genetic model, with results being based
solely on a per-allele analysis in 24% of the papers versus
21% (P ¼ 0.653). Interestingly, in our review, only 6 of the
25 papers (24%) that used solely a per-allele analysis per-
formed a test for HWE, even though HWE is required for
such a per-allele test. Similarly, only 1 of those 25 (4%)
provided a reason for choosing an additive genetic model.
For papers using per-genotype analyses, the proportion of
those assuming a specific genetic model did not change: 33%
in older meta-analyses versus 27% in recent ones (P¼ 0.53).
Among these meta-analyses, the proportion of papers in
which investigators provided justification for their model
choice was even lower for recent meta-analyses than for
older ones (25% vs. 67%; P ¼ 0.016).
Comparison with quality in other ﬁelds. The results
shown in Table 4 suggest that the quality of meta-analysis
across different fields of research varies widely. When
comparing meta-analyses published before 2002 with the
more recent ones, a time trend of improvement is notice-
able for all items, apart from the assessment of publication
bias. This important issue seems to be consistently over-
looked in meta-analysis across fields and over time, with
the exception of the papers included in our review. No clear
difference is evident between reviews on meta-analyses of
randomized clinical trials and reviews which include meta-
analyses of other study designs. The quality of Cochrane
systematic reviews and meta-analyses is reported to be
higher, with the exception of the 2002 paper by Shea
et al. (54), where Cochrane papers were found to score
no better, and for some quality items even worse, than
others (Table 4). The authors suggested that this finding
was due to low quality of reporting rather than conduct,
and they pointed out how the Cochrane Collaboration had
taken steps to improve the quality of its reviews in the
period since their study (54).
DISCUSSION
The general quality of current genetic meta-analyses is
very variable, although on average it is similar to that ob-
served in other fields of medicine, and there is evidence of
an improvement since Attia et al.’s earlier review (4). Rec-
ognition of potential problems, such as publication bias, is
not always accompanied by appropriate action. The quality
of the handling of specifically genetic factors is disappoint-
ingly low and does not seem to be improving. HuGE reviews
scored better than the other analyses in this respect, but the
comparison is hard to interpret because of the relatively
small numbers.
Quality was markedly poorer in the 26% of the meta-
analyses that accompanied the report of a primary study.
This may reflect partly the expertise of the authors and the
time available for performing the meta-analysis and partly
the amount of space available in a given journal. Investiga-
tors sometimes add a meta-analysis in order to put their
results into context. Although this is, in principle, a way
of strengthening the evidence, it can lead to a ‘‘quick-and-
dirty’’ meta-analysis. A poorly conducted or poorly reported
meta-analysis is of little scientific use and may mislead. If
space is a problem, details should be posted on a Web site.
The use of quality scores has limitations, in the same way
as shown for the quality assessment of primary studies in-
cluded in systematic reviews and meta-analyses (9). Our
interest was to evaluate individual quality components,
and we used scores only as convenient summaries for com-
paring quality across different types of meta-analyses. We
created 2 quality scores, one with general quality indicators
and the other with quality indicators specific to genetics,
based on our subjective judgment. It is interesting that when
a more objective approach to the assessment of quality was
applied using PCA, the correspondence of the PCA-derived
scores with our subjective scores was very high. The only
exception was an item that we had selected as a genetic
indicator of good quality—the consideration of biomarkers
or intermediate phenotypes in the paper—which proved not
to be a good marker of quality in the PCA. When this item
was deleted from the genetic score, the correlation between
‘‘subjective’’ and ‘‘objective’’ scores was 96%. The PCA
results suggest that the quality indicators used in this paper,
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when taken as a set, can discriminate well between meta-
analyses of good and poor quality, even if individually they
have differing relevance and impact on quality. The results
of the PCA also suggest that fewer indicators might be
equally able to discriminate between good and poor quality
for both the general and the genetic aspects of meta-
analysis.
Recommendations
Stating the rationale for the meta-analysis. We found that
the rationale for the meta-analysis was often not stated
clearly. A meta-analysis might be exploratory or it might,
for instance, be intended to replicate or support a result from
a primary study or to evaluate sources of heterogeneity.
When a finding from a primary study is conclusive, the
aim of a meta-analysis may be to see whether the same
association holds in other populations; when it is not con-
clusive, the aim might be to see whether it becomes so when
combined with evidence from other studies. In the former
case, the meta-analysis would not include the primary study,
while in the latter it would. However, in our review, all 31
meta-analyses which accompanied a primary study included
that study in the meta-analysis.
Identiﬁcation and selection of studies. Although the ma-
jority of the authors in our review described their search
strategy, few of them did so in a way that allowed reproduc-
ibility. Details on the search strategy could be made avail-
able as Web material if space were limited. The numbers of
papers identified at each stage should be reported, possibly
using the flow diagram suggested in the QUOROM state-
ment (10). In our review, fewer than one-fourth of the meta-
analyses provided this information.
There is no consensus on whether combining family- and
population-based studies within a single meta-analysis is
appropriate, the main concern being that gene-gene and
gene-environment interactions might play different roles
in the 2 types of studies. However, a number of authors have
argued in favor of their combination (11–13), and this is
recommended in the HuGE Review Handbook (14) when
the available evidence is limited. Family studies based on
the transmission disequilibrium test can be combined with
population-based studies that use a per-allele approach, pro-
vided that the assumptions of additivity and HWE hold.
When family- and population-based studies are combined,
it is important to perform a sensitivity analysis.
Study identification is time-consuming, which may ex-
plain why only 13% of the papers in our review included
a duplicate reading of the titles and abstracts. However, this
is an important step that protects against selection bias. The
selected articles should be read and information extracted
onto a predesigned data extraction form, again in duplicate.
In the meta-analyses included in our review, duplicate data
extraction was performed in 28% of all papers and 50% of
the HuGE reviews.
Choice of the genetic model. A key decision in any meta-
analysis is which genetic model to adopt. In our review, 1 in
5 papers used a per-allele analysis. This requires an additive
model and HWE (15). However, these assumptions are often
ignored. In only 1 (4%) of the papers that relied on a per-
allele analysis did investigators provide a reason, and in only
one-fourth did they test for HWE. For the per-genotype
approach, a genetic model was assumed in approximately
one-fourth of the papers reviewed. The assumption of a ge-
netic model increases statistical power, but there must be
a priori knowledge to support the choice. In practice, there is
often only poor-quality information on the genetic model,
especially when the allele frequency is low. Among meta-
analyses that assumed a genetic model, in only one-fourth of
the papers did the authors provide justification for their
choice. Assuming a ‘‘wrong’’ genetic model is a potential
source of bias (16). When the underlying genetic model is
unknown, it is better to use pairwise comparisons of the 3
genotypes, and the loss of power may be limited through the
use of a bivariate meta-analysis (17). Alternatively, data can
be utilized more efficiently using a ‘‘genetic model-free’’
approach, which estimates the genetic model from the data
(16, 17).
Assessment of heterogeneity. Assessing the presence
of between-study heterogeneity is a crucial step in any
meta-analysis. In the vast majority of the meta-analyses
reviewed, investigators performed a statistical test for
heterogeneity, although only one-third of them estimated
its magnitude. Testing for heterogeneity alone is unsat-
isfactory, not only because it does not provide evidence
on the extent of the problem but also because of the low
power of the tests. The magnitude of heterogeneity can
be directly measured by the between-study variance. In
the meta-analyses reviewed, heterogeneity was mainly
quantified using I2, a measure proposed by Higgins et al.
(18) and defined as the percentage of total variation in
study estimates explained by heterogeneity rather than
sampling error. However, as Higgins and Thompson
(19) have pointed out, I2 better describes the impact of
heterogeneity on the meta-analysis than the magnitude of
heterogeneity.
If the studies are heterogeneous in a way not anticipated
in the hypothesis, the first priority should be to investigate
the causes. Perhaps heterogeneity is due to a few aberrant
studies, or perhaps it is due to geographic or methodological
factors. This can be evaluated by means of meta-regression
or by using subgroup analyses accompanied by formal test-
ing, although statistical significance has to be interpreted in
the light of the low power of interaction tests (20). In the
review, subgroup analyses were performed in 70% of the
meta-analyses, but only 10% formally tested for interaction.
Meta-regression based on study-level characteristics was
used in 18% of the papers, while patient-level characteristics
were used in 13%. Without individual patient data, the use
of patient-level characteristics in meta-regression should be
discouraged, as it is difficult to interpret (21) and has very
little power to explain heterogeneity (22).
Ideally, study quality should be investigated as a cause of
heterogeneity. Our review shows that this is rarely done,
perhaps because there is no consensus on the best quality
scoring model. Although many authors have proposed
checklists (1, 23–26), no synthesis of this work has been
carried out.
Use of random effects. When unanticipated heterogene-
ity cannot be explained, a decision needs to be made on
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Table 4. Results of Reviews on Quality of Meta-Analyses Across Different Fields of Research
Authors and Year
(Ref. No.)
Field of Research
(Type of Primary Studies)
No. of M-A’s
Publication
Date(s) of M-A’s
Quality Indicator (% of M-A’s Fulﬁlling the Criterion)
Search
Methods
Reported
Inclusion
Criteria
Reported
Pooling
Methods
Reported
Statistical
Heterogeneity
Assessed
Publication
Bias
Assessed
Current review Genetic epidemiology
(genetic association studies)
120 2005–2007 86 74 97 93 71
Attia et al., 2003 (4) Genetic epidemiology
(genetic association studies)
37 1991–2000 65 49 97 76 19
De Vito et al., 2007 (37)a Vaccinology (all study designs) 121 1991–2007
(February)
87 79 79 67 26
Junhua et al., 2007 (38) Traditional Chinese medicine (NS) 36 1978–2006 78 81 67 NR NR
Gerber et al., 2007 (39)b Any ﬁeld (mostly RCTs) 272 1993–2002 85 NR 100 85 21
Sheik et al., 2007 (40)a Maternal medicine (NS) 39 Cochrane 2001–2006 97 100 NR NR NR
29 others 90 59 NR NR NR
Boluyt et al., 2006 (41) Asthma (randomized and
quasi-randomized trials)
14 Cochrane 2000–2006 100 100 100 74 NR
9 others 1992–2005 89 78 67
Collier et al., 2006 (42)a Dermatology (mostly RCTs) 28 Cochrane 1999–2004 100 96 71 NR NR
10 others 1999–2005 90 70 60 NR NR
Flores-Mir et al., 2006 (43)a Orthodontics (NS) 16 2000–2004 88 100 NR NR NR
Golder et al., 2006 (44)a Adverse effects (all study designs) 256 1994–2005 77 NR NR 88 NR
Jorgensen et al., 2006 (45) Any ﬁeld (mostly RCTs) 24 Cochrane 1996–2003 96 100 100 NR NR
24 others 75 83 96 NR NR
Shea et al., 2006 (46)a Musculoskeletal diseases 57 Cochrane Up to 2002 88 100 95 NR NR
Shea et al., 2006 (47)a Any ﬁeld (mostly RCTs) 53 Cochrane
original
Up to 2002 81 98 89 NR NR
53 Cochrane
updated
87 91 83 NR NR
Delaney et al., 2005 and
2007 (48, 49)
Critical care medicine (NS) 47 Cochrane 1994–2003 100 98 81 NR NR
92 others 91 78 78 NR NR
Dixon et al., 2005 (50) General surgical literature (NS) 51 1997–2002 67 70 67 NR NR
Lawson et al., 2005 (51) Conventional medicine and
complementary/alternative
medicine (RCTs)
105 conventional Up to 1999 49 74 77 NR 15
25 complementary 68 100 84 NR 16
Palma and Delgado-
Rodriguez, 2005 (52)
Cardiovascular (all study designs) 225 1990–2002 NRc NRc NRc 83 11
Moher et al., 2002 (53) Pediatric alternative and
conventional medicine (NS)
66 NS–2001 52 64 41 38 17
Shea et al., 2002 (54) Any ﬁeld (RCTs) 52 Cochrane 1993–1996 31 74 98 29 8
52 others 1990–1995 64 46 85 65 17
Bhandari et al., 2001 (55) Orthopedic surgery (RCTs and
observational studies)
40 1984–1999 83 78 70 NR NR
Choi et al., 2001 (56) Anesthesia (NS) 82 1989–1999 73 81 82 35 5
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whether to continue with the analysis using a random-
effects model (27) or to refrain from pooling. Forcing
a random-effects meta-analysis in the presence of large
heterogeneity can produce an average estimate that is
meaningless. An extreme example of this is genetic
‘‘flip-flop’’ (28, 29), where results from primary studies
are significant but point in opposite directions. A meta-
analysis which combines such studies might misleadingly
suggest a lack of genetic effect. There are no clear guide-
lines on how much heterogeneity is allowable, but as
a rough guide, we would suggest only using a random-
effects model if the standard deviation of the between-
study variation is less than 25% of the pooled effect
size—for instance, a log odds ratio.
Evaluation of HWE. HWE should be investigated in the
individual studies, since deviation from HWE may reflect
methodological problems, such as genotyping error, popu-
lation stratification, or selection bias (30). Because of low
statistical power, it is advisable to measure the magnitude of
the deviation from HWE as well as its significance. In our
review, HWE was assessed in 41% of the recent papers, and
the assessment was limited to statistical testing, apart from 3
meta-analyses in which the magnitude of the deviation was
used to adjust the final pooled estimate of the genetic effect.
We suggest that lack of HWE should be treated as a reason
for further investigation of a primary study rather than as
grounds for its exclusion (4, 31).
Evaluation of publication bias. Although publication bias
was more frequently considered in our review than in most
others, in only half of the papers did investigators report
using a funnel plot, and slightly more than half reported
using a statistical test. Graphical assessment of the possible
presence of publication bias is simple and useful. However,
judgment based only on visual inspection of funnel plots
tends to be inaccurate, as suggested by empirical evaluation
(32), and funnel plots are best used in conjunction with a test.
A number of tests for publication bias have been proposed,
and the choice between them depends on characteristics of
the meta-analysis (33). If publication bias is suspected, it
may be sensible to concentrate the analysis on the larger
studies or to model the dependence on sample size (34).
Publication might be faster for studies with positive findings
(time-lag bias) (35), and the use of cumulative and recursive
meta-analysis can help detect time trends in effect estimates
(36). In our review, cumulative meta-analysis was per-
formed in only 16% of the papers.
Reporting of study-speciﬁc data. Generally, with the ex-
ception of HuGE reviews, the reporting of study character-
istics needs to be improved. Neither genotype nor allele
counts were reported in nearly half of the meta-analyses.
Additional material can easily be placed on a Web page, and
journal editors and reviewers should encourage this. Other
information that should be reported includes the prevalence
of the risk allele, linkage disequilibrium in the region, gen-
otyping error rates, and any haplotypes or biomarkers that
have been investigated. With the exception of the prevalence
of the polymorphisms, which was reported in the majority of
HuGE reviews and one-third of the others, such data were
rarely given.
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Conclusions
Although the general quality of genetic meta-analyses is
similar to that observed in other fields of medicine and
shows improvement over time, the quality of the handling
of specifically genetic factors is disappointingly low and
does not seem to be improving. This is perhaps not surpris-
ing, given the lack of consensus in the theoretical literature
on the best methods to use. The tendency towards better
quality of HuGE reviews suggests that the HuGE Review
Handbook (14) has positively influenced the conduct and
reporting of such meta-analyses, but there is still a long
way to go. Meta-analysis features very highly in the hierar-
chy of evidence, so it is incumbent on investigators perform-
ing meta-analyses to be as methodologically rigorous as
possible. Development of formal, detailed consensus guide-
lines, similar to those of QUOROM (10), would be helpful.
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